SynthesisGenes2026
Association of SCARB1 Polymorphisms with Coronary Artery Disease Risk: A Systematic Review and Meta-Analysis.
Synthesis in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCoronary artery disease (CAD) remains a major cause of morbidity and mortality worldwide. Variants in the lipid metabolism gene SCARB1 may influence CAD susceptibility, but existing evidence is inconsistent.
methodsWe systematically searched PubMed, Embase, Web of Science, the Cochrane Library, and Scopus up to 13 February 2026 for case-control studies on SCARB1 polymorphisms and CAD risk. Three polymorphisms, rs5888, rs4238001, and rs10846744, were included. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated under multiple genetic models. Subgroup analyses were conducted for rs5888 by sex, ethnicity, and clinical outcome. Heterogeneity was assessed using I
results12 eligible case-control studies involving 3947 CAD cases and 5076 controls were included. Overall, rs5888 was not significantly associated with CAD in any genetic model, either in the pooled analysis or in subgroup analyses by ethnicity and clinical outcome. In sex-stratified analyses, males carrying the TT genotype had a significantly lower CAD risk under the recessive model (OR = 0.73, 95% CI: 0.57-0.93), whereas no significant association was observed in females. No significant association was found between rs4238001 and CAD under any model. In contrast, the rs10846744 G allele was significantly associated with reduced CAD risk under the allelic (OR = 0.78, 95% CI: 0.64-0.94), dominant (OR = 0.68, 95% CI: 0.50-0.93), homozygote (OR = 0.65, 95% CI: 0.44-0.94), and additive models (OR = 0.80, 95% CI: 0.67-0.96).
conclusionsSCARB1 rs5888 showed a male-specific association with CAD, while rs10846744 showed a suggestive inverse association that requires further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.